In deal with Altaris Capital, “I don't feel like we got out at any cost,” says Perrigo CEO Murray Kessler. Agreement calls for “a number of mutual long-term relationship components ... including on Rx-to-OTC switches."
Divesting its Rx generics business took a disproportionate amount of time considering Perrigo Company PLC’s been operating for more than 130 years and it’s been in the prescription drug space for around 15 years.
Still, with the deal with Altaris Capital Partners LLC announced on 1 March, “I don't feel like we got out at any cost,” said
Private equity firm CD&R takes control of Opella while Sanofi retains a sizeable stake and nets €10bn.
Wellnex bringing brands such as Pain Away, Wakey Wakey and Nighty Night to UK market shortly after gaining admission to the the AIM market of the London Stock Exchange.
The firms recently announced they will operate as combined company LXE Hearing marketing Eargo’s namesake line and hearX’s Lexie brands. Eargo majority owner Patient Square Capital added $100m to its investment.
Consumer health player Karo is changing hands from EQT to KKR in a deal thought to value the Stockholm-based firm at over €2.5bn.
A round-up of the latest consumer health leadership changes: Haleon names Middle East & Africa unit manager; Wellnex Life appoints interim chair; Orkla Health appoints CEO.
Private equity firm CD&R takes control of Opella while Sanofi retains a sizeable stake and nets €10bn.
Germany-based firm grew three-times faster than the OTC pharmacy market in 2024 and is hoping to continue this momentum in 2025.
